Skip to main content
SpringerLink
Log in

Improved in vivo efficacy of tumor-infiltrating lymphocytes after restimulation with irradiated tumor cells in vitro

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background: We investigated different culture conditions for tumor-infiltrating lymphocytes (TILs) with regard to proliferation, phenotypic changes, in vitro cytotoxicity, and in vivo therapeutic efficacy.

Methods: After enzymatic digestion of the murine fibrosarcoma, MCA-105, TIL cultures were initiated as pure lymphocyte (groups 1 and 2) or mixed lymphocyte/tumor suspensions (groups 3 and 4). Group 1 TILs were grown in culture medium containing 100 IU/ml recombinant interleukin-2 (rIL-2). Group 2 TILs were stimulated with solid-phase anti-CD3 monoclonal antibody (mAb) for 48 h and cultured in rIL-2 (100 IU/ml)-containing medium. Group 3, which consisted initially of a surplus of tumor cells, received the same treatment as group 2. Group 4 was also activated with anti-CD3 mAb and rIL-2 but was additionally restimulated weekly with irradiated tumor cells (TILs to tumor, 20:1).

Results: Groups 1 and 2 showed up to twofold higher increases in TIL numbers compared with groups 3 and 4 by the end of culture week 5. Although the original lymphocyte/tumor cell suspension consisted of 12.0 ± 3.8% CD4+ T cells and 5.3 ± 3.3% CD8+ T cells, all four TIL cultures showed ∼80% CD8+ TILs and no CD4+ TILs by the end of culture week 4. In vitro cytotoxicity did not correlate with in vivo efficacy of the examined TIL cultures. By using the MCA-105 pulmonary metastases model in C57BL/6 mice, only suboptimal doses of TILs (2 × 106) from group 4, which had been restimulated weekly with irradiated tumor, showed significant tumor eradication compared with all other treatment groups (p<0.01).

Conclusions: We conclude that in vitro tumor restimulation of TILs improves in vivo efficacy, most likely through the education of tumor-reactive T cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.Science 1986;233:1318–21.

    CAS  PubMed  Google Scholar 

  2. Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.J Natl Cancer Inst 1987;79:1067–75.

    CAS  PubMed  Google Scholar 

  3. Burger UL, Chang MP, Goedegebuure PS, Eberlein TJ. Tumor eradication by tumor-infiltrating lymphocytes and rIL-2 requires the recruitment of host CD8+ T cells.Surgery 1995;117:325–33.

    CAS  PubMed  Google Scholar 

  4. Massaro AF, Schoof DD, Rubinstein A, Zuber M, Leonard-Vidal FJ, Eberlein TJ. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.Cancer Res 1990;50:2587–92.

    CAS  PubMed  Google Scholar 

  5. Goedegebuure PS, Douville L, Li H, et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma.J Clin Oncol 1995;13:1939–49.

    CAS  PubMed  Google Scholar 

  6. Goedegebuure PS, Zuber M, Leonard-Vidal DL, et al. Reactivation of murine tumor-infiltrating lymphocytes with solid-phase anti-CD3 antibody: in vitro cytokine production is associated with in vivo efficacy.Surg Oncol 1994;3:79–89.

    Article  CAS  PubMed  Google Scholar 

  7. Peoples GE, Schoof DD, Raven Andrews JV, Goedegebuure PS, Eberlein TJ. T cell recognition of ovarian cancer.Surgery 1993;114:227–34.

    CAS  PubMed  Google Scholar 

  8. Yoshino I, Goedegebuure PS, Peoples GE, et al. HER2/neuderived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.Cancer Res 1994;54:3387–90.

    CAS  PubMed  Google Scholar 

  9. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.Proc Natl Acad Sci USA 1995;92:432–6.

    CAS  PubMed  Google Scholar 

  10. Matsumura T, Sussman JJ, Krinock RA, Chang AE, Shu S. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.Cancer Res 1994;54:2744–50.

    CAS  PubMed  Google Scholar 

  11. Parker GA, Rosenberg SA. Serologic identification of multiple tumor-associated antigens on murine sarcomas.J Natl Cancer Inst 1977;58:1303–9.

    CAS  PubMed  Google Scholar 

  12. Shu S, Rosenberg SA. Adoptive immunotherapy of newly induced murine sarcomas.Cancer Res 1985;45:1657–62.

    CAS  PubMed  Google Scholar 

  13. Damle NK, Doyle LV, Bradley EC. Interleukin-2 activated human killer cells are phenotypically heterogeneous precursors.J Immunol 1986;137:2814–22.

    CAS  PubMed  Google Scholar 

  14. Fekete E. A comparative morphological study of the mammary gland in a high and low tumor strain of mice.Am J Pathol 1938;14:557–78.

    Google Scholar 

  15. Wexler H. Accurate identification of experimental pulmonary metastases.J Natl Cancer Inst 1966;36:641–5.

    CAS  PubMed  Google Scholar 

  16. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily single-censored samples.Biometrica 1965;52:203–17.

    CAS  Google Scholar 

  17. Barth RJ JR, Mulé JJ, Spiess PJ, Rosenberg SA. Interferon-γ and tumor necrosis factor have a role in tumor regression mediated by murine CD8+ tumor-infiltrating lymphoytes.J Exp Med 1991;173:647–58.

    Article  CAS  PubMed  Google Scholar 

  18. Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma.N Engl J Med 1988;25:1676–80.

    Google Scholar 

  19. Aebersold P, Hyatt C, Johnson S, et al. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.J Natl Cancer Inst 1991;83:932–7.

    CAS  PubMed  Google Scholar 

  20. Topalian SL, Solomon D, Avis FP, et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.J Clin Oncol 1988;6:839–53.

    CAS  PubMed  Google Scholar 

  21. Eberlein TJ, Schoof DD, Jung S-E, et al. A new regimen of interleukin 2 and lymphokine-activated killer cells: efficacy without significant toxicity.Arch Intern Med 1988;148:2571–6.

    Article  CAS  PubMed  Google Scholar 

  22. Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.Cancer Res 1988;48:5007–10.

    CAS  PubMed  Google Scholar 

  23. Eberlein TJ, Rodrick ML, Massaro AF, Jung S-E, Mannick JA, Schoof DD. Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans.Cancer Immunol Immunother 1989;30:145–50.

    Article  CAS  PubMed  Google Scholar 

  24. Schoof DD, Selleck C, Massaro AF, Jung S-E, Eberlein TJ. Activation of human tumor-infiltrating lymphocytes by monoclonal antibodies directed to the CD3 complex.Cancer Res 1990;50:1138–43.

    CAS  PubMed  Google Scholar 

  25. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for murine T3 polypeptide.Proc Natl Acad Sci USA 1987;84:1374–8.

    CAS  PubMed  Google Scholar 

  26. Clevers H, Alarcon B, Wileman T, Terhorst C. The T cell receptor/CD3 complex: a dynamic protein ensemble.Annu Rev Immunol 1988;6:629–62.

    Article  CAS  PubMed  Google Scholar 

  27. Emmrich F, Moll H, Simon MM. Recombinant human interleukin-2 acts as a B-cell growth and differentiation promoting factor.Immunobiology 1985;169:97–102.

    CAS  PubMed  Google Scholar 

  28. Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.Cancer Res 1981;41:4420–5.

    CAS  PubMed  Google Scholar 

  29. Domzig W, Stadler BM, Herbermann RB. Interleukin-2 dependence of human natural killer (NK) cell activity.J Immunol 1983;130:1970–3.

    CAS  PubMed  Google Scholar 

  30. Nagoshi M, Goedegebuure PS, Burger UL, Chang MP, Eberlein TJ. Successful adoptive immunotherapy (AIT) is dependent on the infiltration of host CD8+ and CD4+ T cells into tumor.Surg Forum 1995;46:528–31.

    Google Scholar 

  31. Linehan DC, Peoples GE, Hess DT, et al. In vitro stimulation of ovarian tumour-associated lymphocytes with a peptide derived from HER2/neu induces cytotoxicity against autologous tumour.Surg Oncol 1995;4:41–9.

    CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Ulrike L. Burger MD

    Present address: Surgical University Hospital, University of Heidelberg, INF 110, 69120, Heidelberg, Germany

Authors and Affiliations

  1. From the Department of Surgery, Division of Surgical Oncology, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

    Ulrike L. Burger MD, Maximilian P. Chang BA, Makoto Nagoshi MD, Peter S. Goedegebuure PhD &  Timothy J. Eberlein MD

Authors
  1. Ulrike L. Burger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maximilian P. Chang BA
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Makoto Nagoshi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter S. Goedegebuure PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Timothy J. Eberlein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Burger, U.L., Chang, M.P., Nagoshi, M. et al. Improved in vivo efficacy of tumor-infiltrating lymphocytes after restimulation with irradiated tumor cells in vitro. Annals of Surgical Oncology 3, 580–587 (1996). https://doi.org/10.1007/BF02306093

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02306093

Key Words

Search

Navigation